Selected research
Industry Research
Ophthalmic Corticosteroid Industry Research Report 2026
Market perspective
The global Ophthalmic Corticosteroid market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Ophthalmic Corticosteroid market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Ophthalmic Corticosteroid market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Ophthalmic Corticosteroid market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Ophthalmic Corticosteroid include Novartis AG, Pfizer, GlaxoSmithKline, Bayer AG, Sun Pharmaceutical, Regeneron Pharmaceuticals, Orchidia, Innovative Pharmaceuticals and General Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Ophthalmic Corticosteroid market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Ophthalmic Corticosteroid.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ophthalmic Corticosteroid Market by Company
Novartis AG
Pfizer
GlaxoSmithKline
Bayer AG
Sun Pharmaceutical
Regeneron Pharmaceuticals
Orchidia
Innovative Pharmaceuticals
General Pharmaceuticals
Genentech
Bausch Health
Bausch and Lomb
Allergan
Alimera Sciences
Ajanta Pharma
Ophthalmic Corticosteroid Segment by Type
Dexamethasone
Difluprednate
Fluorometholone
Loteprednol
Others
Ophthalmic Corticosteroid Segment by Application
Hospital Pharmacies
Research Institute
Online Pharmacies
Retail Pharmacies
Others
Ophthalmic Corticosteroid Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ophthalmic Corticosteroid market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ophthalmic Corticosteroid and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ophthalmic Corticosteroid.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Ophthalmic Corticosteroid companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Dexamethasone
- Difluprednate
- Fluorometholone
- Loteprednol
- Others
Applications
- Hospital Pharmacies
- Research Institute
- Online Pharmacies
- Retail Pharmacies
- Others
Companies covered
- Novartis AG
- Pfizer
- GlaxoSmithKline
- Bayer AG
- Sun Pharmaceutical
- Regeneron Pharmaceuticals
- Orchidia
- Innovative Pharmaceuticals
- General Pharmaceuticals
- Genentech
- Bausch Health
- Bausch and Lomb
- Allergan
- Alimera Sciences
- Ajanta Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Ophthalmic Corticosteroid by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Dexamethasone
- 2.2.3 Difluprednate
- 2.2.4 Fluorometholone
- 2.2.5 Loteprednol
- 2.2.6 Others
- 2.3 Ophthalmic Corticosteroid by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacies
- 2.3.3 Research Institute
- 2.3.4 Online Pharmacies
- 2.3.5 Retail Pharmacies
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Ophthalmic Corticosteroid Breakdown Data by Type
- 3.1 Global Ophthalmic Corticosteroid Historic Market Size by Type (2021-2026)
- 3.2 Global Ophthalmic Corticosteroid Forecasted Market Size by Type (2027-2032)
4 Ophthalmic Corticosteroid Breakdown Data by Application
- 4.1 Global Ophthalmic Corticosteroid Historic Market Size by Application (2021-2026)
- 4.2 Global Ophthalmic Corticosteroid Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Ophthalmic Corticosteroid Market Perspective (2021-2032)
- 5.2 Global Ophthalmic Corticosteroid Growth Trends by Region
- 5.2.1 Global Ophthalmic Corticosteroid Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Ophthalmic Corticosteroid Historic Market Size by Region (2021-2026)
- 5.2.3 Ophthalmic Corticosteroid Forecasted Market Size by Region (2027-2032)
- 5.3 Ophthalmic Corticosteroid Market Dynamics
- 5.3.1 Ophthalmic Corticosteroid Industry Trends
- 5.3.2 Ophthalmic Corticosteroid Market Drivers
- 5.3.3 Ophthalmic Corticosteroid Market Challenges
- 5.3.4 Ophthalmic Corticosteroid Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Ophthalmic Corticosteroid Players by Revenue
- 6.1.1 Global Top Ophthalmic Corticosteroid Players by Revenue (2021-2026)
- 6.1.2 Global Ophthalmic Corticosteroid Revenue Market Share by Players (2021-2026)
- 6.2 Global Ophthalmic Corticosteroid Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Ophthalmic Corticosteroid Head Office and Area Served
- 6.4 Global Ophthalmic Corticosteroid Players, Product Type & Application
- 6.5 Global Ophthalmic Corticosteroid Manufacturers Established Date
- 6.6 Global Ophthalmic Corticosteroid Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Ophthalmic Corticosteroid Market Size (2021-2032)
- 7.2 North America Ophthalmic Corticosteroid Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Ophthalmic Corticosteroid Market Size by Country (2021-2026)
- 7.4 North America Ophthalmic Corticosteroid Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Ophthalmic Corticosteroid Market Size (2021-2032)
- 8.2 Europe Ophthalmic Corticosteroid Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Ophthalmic Corticosteroid Market Size by Country (2021-2026)
- 8.4 Europe Ophthalmic Corticosteroid Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Ophthalmic Corticosteroid Market Size (2021-2032)
- 9.2 Asia-Pacific Ophthalmic Corticosteroid Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Ophthalmic Corticosteroid Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Ophthalmic Corticosteroid Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Ophthalmic Corticosteroid Market Size (2021-2032)
- 10.2 South America Ophthalmic Corticosteroid Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Ophthalmic Corticosteroid Market Size by Country (2021-2026)
- 10.4 South America Ophthalmic Corticosteroid Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Ophthalmic Corticosteroid Market Size (2021-2032)
- 11.2 Middle East & Africa Ophthalmic Corticosteroid Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Ophthalmic Corticosteroid Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Ophthalmic Corticosteroid Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.1.4 Novartis AG Ophthalmic Corticosteroid Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Pfizer
- 12.2.1 Pfizer Company Information
- 12.2.2 Pfizer Business Overview
- 12.2.3 Pfizer Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.2.4 Pfizer Ophthalmic Corticosteroid Product Portfolio
- 12.2.5 Pfizer Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.3.4 GlaxoSmithKline Ophthalmic Corticosteroid Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Bayer AG
- 12.4.1 Bayer AG Company Information
- 12.4.2 Bayer AG Business Overview
- 12.4.3 Bayer AG Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.4.4 Bayer AG Ophthalmic Corticosteroid Product Portfolio
- 12.4.5 Bayer AG Recent Developments
- 12.5 Sun Pharmaceutical
- 12.5.1 Sun Pharmaceutical Company Information
- 12.5.2 Sun Pharmaceutical Business Overview
- 12.5.3 Sun Pharmaceutical Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.5.4 Sun Pharmaceutical Ophthalmic Corticosteroid Product Portfolio
- 12.5.5 Sun Pharmaceutical Recent Developments
- 12.6 Regeneron Pharmaceuticals
- 12.6.1 Regeneron Pharmaceuticals Company Information
- 12.6.2 Regeneron Pharmaceuticals Business Overview
- 12.6.3 Regeneron Pharmaceuticals Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.6.4 Regeneron Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
- 12.6.5 Regeneron Pharmaceuticals Recent Developments
- 12.7 Orchidia
- 12.7.1 Orchidia Company Information
- 12.7.2 Orchidia Business Overview
- 12.7.3 Orchidia Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.7.4 Orchidia Ophthalmic Corticosteroid Product Portfolio
- 12.7.5 Orchidia Recent Developments
- 12.8 Innovative Pharmaceuticals
- 12.8.1 Innovative Pharmaceuticals Company Information
- 12.8.2 Innovative Pharmaceuticals Business Overview
- 12.8.3 Innovative Pharmaceuticals Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.8.4 Innovative Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
- 12.8.5 Innovative Pharmaceuticals Recent Developments
- 12.9 General Pharmaceuticals
- 12.9.1 General Pharmaceuticals Company Information
- 12.9.2 General Pharmaceuticals Business Overview
- 12.9.3 General Pharmaceuticals Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.9.4 General Pharmaceuticals Ophthalmic Corticosteroid Product Portfolio
- 12.9.5 General Pharmaceuticals Recent Developments
- 12.10 Genentech
- 12.10.1 Genentech Company Information
- 12.10.2 Genentech Business Overview
- 12.10.3 Genentech Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.10.4 Genentech Ophthalmic Corticosteroid Product Portfolio
- 12.10.5 Genentech Recent Developments
- 12.11 Bausch Health
- 12.11.1 Bausch Health Company Information
- 12.11.2 Bausch Health Business Overview
- 12.11.3 Bausch Health Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.11.4 Bausch Health Ophthalmic Corticosteroid Product Portfolio
- 12.11.5 Bausch Health Recent Developments
- 12.12 Bausch and Lomb
- 12.12.1 Bausch and Lomb Company Information
- 12.12.2 Bausch and Lomb Business Overview
- 12.12.3 Bausch and Lomb Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.12.4 Bausch and Lomb Ophthalmic Corticosteroid Product Portfolio
- 12.12.5 Bausch and Lomb Recent Developments
- 12.13 Allergan
- 12.13.1 Allergan Company Information
- 12.13.2 Allergan Business Overview
- 12.13.3 Allergan Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.13.4 Allergan Ophthalmic Corticosteroid Product Portfolio
- 12.13.5 Allergan Recent Developments
- 12.14 Alimera Sciences
- 12.14.1 Alimera Sciences Company Information
- 12.14.2 Alimera Sciences Business Overview
- 12.14.3 Alimera Sciences Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.14.4 Alimera Sciences Ophthalmic Corticosteroid Product Portfolio
- 12.14.5 Alimera Sciences Recent Developments
- 12.15 Ajanta Pharma
- 12.15.1 Ajanta Pharma Company Information
- 12.15.2 Ajanta Pharma Business Overview
- 12.15.3 Ajanta Pharma Revenue in Ophthalmic Corticosteroid Business (2021-2026)
- 12.15.4 Ajanta Pharma Ophthalmic Corticosteroid Product Portfolio
- 12.15.5 Ajanta Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst